Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 5 September 2026
2019-09-17 08:33:00 Tuesday ET
Global stock market investors foresee the harbinger of a major economic downturn. Many stock market investors become anxious due to negative term spreads an
2018-01-02 12:39:00 Tuesday ET
Goldman Sachs takes a $5 billion net income hit that results from its offshore cash repatriation under the new Trump tax law. This income hit reflects 10%-1
2018-11-09 11:35:00 Friday ET
The Internet inventor Tim Berners-Lee suggests that several tech titans might need to be split up in response to some recent data breach and privacy concern
2020-09-24 10:26:00 Thursday ET
Edge strategies help business leaders improve core products and services in a more cost-effective and less risky way. Alan Lewis and Dan McKone (2016)
2018-09-27 11:41:00 Thursday ET
Michael Kors pays $2.3 billion to acquire the Italian elite fashion brand Versace. In accordance with Michael Kors's 5-year plan, the joint company grow
2023-05-07 10:27:00 Sunday ET
William Easterly critiques several economic development policies and then indicates that bottom-up solutions often result in macro policy success in spite o
Statement
Ratio
News